Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in patients with newly diagnosed pancreatic cancer.

Sci Rep · 2025 · PMC12494785 · PMID 41044171

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Furthermore, ctDNA samples and tumor samples in the ctDNA high group showed a trend towards higher prevalence of 12p chromosomal gains (including KRAS ) compared to the ctDNA low group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.